BridgeBio Pharma stock stood 26.9 percent below its 52-week high on October 16, 2026

Published on 10/17/2026 at 21:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Market value was USD 13.0 billion on October 16, 2026. BridgeBio Pharma stock last stood at EUR 58.98 on gettex on October 16, 2026, below EUR 80.73.

Trading range and valuation

BridgeBio Pharma fell 1.10 percent on Nasdaq on October 16, 2026.
BridgeBio Pharma posted a price-to-earnings ratio of minus 18.54 on October 16, 2026.
BridgeBio Pharma stock stood at EUR 58.98 at 8:43 p.m. CEST on gettex on October 16, 2026, 26.9 percent below the 52-week high.
The FDA target action date for BBP-418 is November 27, 2026.

BBIO, US10806X1028, Illustration mit AI erstellt.

BridgeBio Pharma stock stood 26.9 percent below its 52-week high of EUR 80.73 on October 16, 2026. The last gettex quote stood at EUR 58.98 at 8:43 p.m. CEST.

52-week range leaves room

The same October 16 quote placed the session range between EUR 58.38 and EUR 59.73, with a bid of EUR 58.45 and an ask of EUR 59.47. The quote also listed 44 shares in volume, keeping the day range narrow around the last price.

At EUR 58.98, the stock was 30.5 percent above its 52-week low of EUR 45.18. Its Nasdaq listing was last at USD 66.39 on October 16, 2026 at 4:00 p.m. ET, down 1.10 percent from the prior close.

Valuation remains loss-making

BridgeBio Pharma had a market capitalization of USD 13.0 billion on October 16, 2026. Its price-to-earnings ratio was minus 18.54, while Alnylam Pharmaceuticals carried a ratio of 39.16 and Ionis Pharmaceuticals a ratio of minus 12.41 on the same date.

The company describes its business as developing medicines for genetic conditions. According to BridgeBio Pharma, its portfolio includes programs ranging from discovery research to late-stage clinical development.

November 27 brings a regulatory date

BridgeBio's next stated regulatory milestone is November 27, 2026, when the FDA has set a target action date for BBP-418, according to the company's October 5 release.

Comparison with peers

BridgeBio Pharma (Nasdaq, USD): minus 1.10 percent, price-to-earnings ratio minus 18.54, market capitalization USD 13.0 billion

Alnylam Pharmaceuticals (Nasdaq, USD): minus 0.94 percent, price-to-earnings ratio 39.16, market capitalization USD 31.0 billion

Ionis Pharmaceuticals (Nasdaq, USD): minus 2.67 percent, price-to-earnings ratio minus 12.41, market capitalization USD 7.1 billion

Stock stays below its yearly high

The October 16 gettex quote left BridgeBio Pharma EUR 21.75 below its 52-week high and EUR 13.80 above its 52-week low. The US listing closed its regular session with a lower last price than the prior close, while the euro quote remained within its daily range.

The last available euro price was EUR 58.98 on gettex on October 16, 2026 at 8:43 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of BridgeBio Pharma stock.